GSK’s 14 September rally was not just a defensive rotation into pharmaceuticals. The stock moved after two lung-cancer updates that go directly to a long-running valuation question for the UK drugmaker: whether its oncology pipeline can become a visible growth driver rather than a set of distant options.
The most immediate catalyst was Jideytro, or zidesamtinib. GSK said data from the registrational ARROS-1 trial in TKI-naïve ROS1-positive non-small cell lung cancer supported a planned 2026 US supplemental New Drug Application to expand the drug into first-line treatment.2 The readout showed a 94% objective response rate among 94 evaluable patients, 90% progression-free survival at 12 months, and complete clearance of detectable brain tumours in 70% of patients with measurable brain metastases at baseline.2
For investors, that matters because first-line use would move Jideytro closer to a broader commercial setting relatively soon after its July 2026 US approval for previously treated ROS1-positive NSCLC.2
The second update was Ris-Rez, GSK’s B7-H3 antibody-drug conjugate licensed from Hansoh for markets outside Greater China. In China’s ARTEMIS-008 Phase III trial, Ris-Rez reduced the risk of death by 54% versus topotecan in relapsed small-cell lung cancer, with median overall survival of 18.5 months versus 10.3 months.1 GSK said the data were the first Phase III results to demonstrate an overall-survival benefit for a B7-H3 ADC in any tumour type, an important distinction in a field where platform credibility can affect how investors value follow-on indications.1
The market reaction was material. Reuters reported that GSK rose 2.5% to 1,815p earlier on Monday after the positive lung-cancer data, while a later London market wrap said pharma stocks rose 3.8% and GSK gained 4.7% as the FTSE 100 closed higher.57 By the close on 14 September, the shares were reported at 1,854.5p, up 4.63%, outperforming the broader blue-chip index.10
That scale of outperformance suggests investors were not merely buying the sector’s bond-proxy characteristics ahead of central-bank decisions. They were also repricing GSK-specific clinical progress.
Why this readout changes the debate
The investment case for GSK has often rested on defensive attributes: scale, vaccines, HIV exposure, cash generation and dividend appeal. Those features remain relevant, especially in a week when investors were moving into healthcare and consumer staples as bond yields rose and macro uncertainty intensified.7
But the 14 September move was different because the clinical updates addressed two gaps that typically limit pipeline credit in large-cap pharma: timing and breadth.
Jideytro speaks to timing. A planned US regulatory submission in 2026 for first-line ROS1-positive NSCLC gives investors a nearer-term catalyst with a defined regulatory path.2 The dataset is not just a high response-rate headline. The 90% 12-month progression-free-survival rate and intracranial activity are particularly relevant in ROS1-positive lung cancer, where brain metastases and long-term tolerability are central commercial issues.2 The reported 1% discontinuation rate due to treatment-related adverse events also supports the argument that Jideytro may compete on durability and usability, not only tumour response.2
Ris-Rez speaks to breadth. Small-cell lung cancer has historically been a difficult market, with rapid relapse and limited effective later-line options. In ARTEMIS-008, GSK and Hansoh reported improvements across overall survival, progression-free survival, objective response and disease control, while grade 3 or higher treatment-related adverse events were lower than with topotecan.1
GSK holds rights outside mainland China, Hong Kong, Macau and Taiwan, and is running a broader global EMBOLD programme, including a Phase III trial in relapsed extensive-stage SCLC with pivotal data expected next year.1 That global replication question is now central to valuation.
Pipeline credit is rising, but not yet settled
The strongest bull interpretation is that GSK is assembling a lung-cancer franchise with multiple shots on goal: a targeted small molecule in ROS1-positive NSCLC and an ADC platform in small-cell lung cancer and potentially other solid tumours.
MarketScreener cited Jefferies as saying Ris-Rez could be a potentially major and undervalued SCLC asset if the effect is replicated in the global programme, while maintaining a buy rating and 2,500p target.8 That is the clearest sign that some investors and analysts are beginning to treat oncology as a valuation lever rather than a footnote.
The bear case has not disappeared. JP Morgan kept an Underweight rating and 1,700p target after the data, leaving its target below the share price reported during the 14 September move.9 That caution is understandable. Jideytro’s first-line expansion still requires regulatory review, and the ROS1-positive market is a molecularly defined niche rather than a mass-market lung-cancer indication.
Ris-Rez, meanwhile, has produced compelling China Phase III data, but GSK’s ex-China economics depend on whether the survival benefit is reproduced in global trials and how regulators and clinicians compare the asset with emerging ADC competitors.
The valuation implication is not that GSK has suddenly become a pure oncology growth stock. It is that the burden of proof has shifted. Before 14 September, investors could reasonably treat lung cancer as a promising but still under-discounted pipeline story. After the Jideytro and Ris-Rez updates, GSK has one asset with a near-term US filing path in first-line disease and another with Phase III survival evidence in a high-need tumour type.12
What investors should watch next
The next stage is confirmation. For Jideytro, the key milestones are the US supplemental NDA filing, acceptance and any review timeline. Investors will also watch whether regulators are comfortable with a single-arm Phase I/II registrational dataset in a biomarker-defined population, and whether the drug’s intracranial and tolerability profile can support premium positioning.2
For Ris-Rez, the pivotal issue is global translation. The China survival data are powerful, but valuation credit will increase materially only if EMBOLD data outside China support a similar efficacy and safety profile.1 A positive global readout would strengthen the case that GSK’s Hansoh partnership has produced a commercial-scale oncology asset, not just a regionally impressive trial result.
The broader FTSE context still matters. Healthcare’s 3.8% sector gain on 14 September shows that macro-driven defensive demand provided a tailwind.7 But GSK’s outperformance and the specificity of the catalysts point to something more stock-specific. Investors were not only hiding in pharma. They were paying for evidence that GSK’s oncology pipeline may be arriving sooner, with deeper clinical validation, than the market had assumed.
That is why the move deserves to be read as a valuation signal. GSK’s defensive qualities may explain why capital was available for the sector, but Jideytro and Ris-Rez explain why GSK captured so much of it.
Comments